Search

Brussels Declaration on the Recognition of Professional QualificationsThe future of the Harmonisation of the Haematology Curriculum in Europe

On the occasion of the meeting, there was unanimous support for the

“Brussels Declaration on the Recognition of Professional Qualifications” that follows:

The mobility of haematology trainees is of the utmost importance.

Read more

Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing

Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.

Read more

EMA Issues Call for Expressions of Interest for Drug Safety Studies

The purpose of this call is to enable the EMA to obtain fast and reliable answers to questions on safety or benefit/risk concerns, and ultimately facilitating regulatory decision-making.

Read more

Late-Breaking Abstract Submission

Late-breaking abstract procedureThe official late-breaking abstract submission was open from May 3 to 9, 2024 (09:00 CEST). The full late-breaking abstract submission terms & conditions can be found here.

Read more

Evaluation of a single 1.000 mg iron dose as ferric carboxymaltose (FCM) for fatigue treatment in Iron deficient women – PREFER

Fatigue and iron deficiency are prevalent among women of childbearing age. This randomised, placebo-controlled study evaluated the effect of a single intravenous 1.

Read more